A novel combination therapy with telemonitoring and individual insulin titration system for diabetes mellitus
Not Applicable
- Conditions
- Diabetes mellitus
- Registration Number
- JPRN-UMIN000033024
- Lead Sponsor
- The Jikei University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
a) having severe renal dysfunction (serum Cr > 2.5 mg/dl) b) having severe liver dysfunction (3 X the upper limit of normal) c) having severe infection, severe trauma, or pre and post operation d) having diabetic ketosis, diabetic coma, or insulin-dependent diabetes mellitus e) heavy drinker f) being pregnant g) having malignancy h) having visual disorder i) being unsuitable for participation in the trial for any reason, according to the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms enhance insulin sensitivity via telemonitoring and personalized titration in the NOCTIS diabetes trial?
How does the NOCTIS telemonitoring-insulin titration combo compare to standard diabetes management in terms of glycemic control?
Which biomarkers predict response to NOCTIS trial's telemonitoring and personalized insulin therapy in type 2 diabetes patients?
What are the potential adverse events of the NOCTIS combination therapy and how are they managed in clinical practice?
Are there other telemonitoring-based insulin titration systems in development for diabetes mellitus besides the NOCTIS approach?